Medtronic announced in January the beginning of clinical trials to evaluate the TYRX Absorable Antibacterial Envelope, according to a press release.
The new WRAP Infection Clinical trial will evaluate the effectiveness of the envelope in reducing infections in patients with CIEDS at risk for infection.
The press release noted that the trial will enroll 7,000 patients at 225 different sites worldwide.
The FDA gave the envelope clearance in May 2013 and the envelope received CE Mark this past September.
Cleveland-based University Hospitals reimagined peer review and cost strategy — contributing to margin-based accountability and an $18.1 million surplus, according…
Physician assistants can now earn a Doctor of Medical Science degree in as little as six months at the University…
Four health system CEOs traveled to Washington, D.C., April 17 to meet with HHS Secretary Robert F. Kennedy Jr., for…
Comments are closed.
